Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 3/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 4/20 | 0.37 |
| ▸ | PDE5A | O76074 | 3/20 | 0.37 |
| ▸ | PDE6C | P51160 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PLK4 | O00444 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30476568 | 1.00 | GGPS1 (0.41) | GGPS1AHRHTTGBA1PDE5A | |
| SCHEMBL2316755 | 0.85 | AHR (0.43) | AHRHTTGBA1PDE5ASRC | |
| SCHEMBL2315103 | 0.81 | AHR (0.58) | AHR | |
| SCHEMBL19276304 | 0.79 | PIK3CA (0.38) | HTTPLK4 | |
| SCHEMBL2359854 | 0.78 | CYP1A2 (0.57) | AHRHTTPDE5APDE6CPDE4D | |
| SCHEMBL15028171 | 0.77 | TRPV1 (0.38) | AHRHTTGBA1HTR7ADORA2A | |
| SCHEMBL20901549 | 0.75 | JAK2 (0.39) | HTTGBA1PDE5AHTR7ADORA2A | |
| SCHEMBL2357749 | 0.75 | AHR (0.69) | AHRGBA1PDE5APDE6CPDE4D | |
| SCHEMBL21016815 | 0.74 | HTR7 (0.37) | HTTGBA1HTR7ADORA2A | |
| SCHEMBL23991713 | 0.74 | AHR (0.38) | AHRHTTGBA1PDE5AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116568802-A | In vitro method for preparing mature red blood cells | 西湖生物医药科技(上海)有限公司 | 2023-08-08 | — | — | CN | claimed |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | claimed |
| EP-2350078-B1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2019-04-17 | — | — | EP | claimed |
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2017-08-24 | — | — | US | claimed |
| US-9175266-B2 | Enhancement of natural killer (NK) cell proliferation and activity | GAMIDA CELL LTD. (IL) | 2015-11-03 | — | — | US | claimed |
| US-20140023626-A1 | Enhancement of Natural Killer (NK) Cell Proliferation and Activity | GAMIDA CELL INC. | 2014-01-23 | — | — | US | claimed |
| US-20140023623-A1 | Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby | GAMIDA CELL INC. | 2014-01-23 | — | — | US | claimed |
| EP-2350078-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2011-08-03 | — | — | EP | claimed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | claimed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | claimed |
| CN-116568802-A | In vitro method for preparing mature red blood cells | 西湖生物医药科技(上海)有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-3524604-B1 | EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | disclosed |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | disclosed |
| EP-3524604-A1 | EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2019-08-14 | — | — | EP | disclosed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | GGPS1 1559/4885AHR 525/4885HTT 408/4885 |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | GGPS1 1559/4885AHR 525/4885HTT 408/4885 |
| US-20140023626-A1 | Enhancement of Natural Killer (NK) Cell Proliferation and Activity | PBK, IL2, AHR | GGPS1 4506/4885AHR 3/4885HTT 3633/4885 |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | GGPS1 1559/4885AHR 525/4885HTT 408/4885 |
| US-20140023623-A1 | Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby | AHR, HGF, MTNR1A | GGPS1 3923/4885AHR 1/4885HTT 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.